Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Wenfeng Fang, Yuanyuan Zhao, Yongzhong Luo, Runxiang Yang, Yan Huang, Zhiyong He, Hui Zhao, Mingjun Li, Kai Li, Qibing Song, Xiaobo Du, Yulan Sun, Wei Li, Fei Xu, Zhiyu Wang, Kunning Yang, Yun Fan, Baogang Liu, Hongyun Zhao, Ying Hu, Li Jia, Shen Xu, Tienan Yi, Dongqing Lv, Haitao Lan, Mengxia Li, Wenhua Liang, Yongsheng Wang, Hui Yang, Yuming Jia, Yuan Chen, Junguo Lu, Jifeng Feng, Chunling Liu, Ming Zhou, Jianya Zhou, Xianling Liu, Ningning Zhou, Ming He, Xiaorong Dong, Hualin Chen, Yongxing Chen, Haichuan Su, Xiaoling Li, Zhihong Zhang, Lei Yang, Ying Cheng, Likun Chen, Xue Hou, Yu Zhang, Jun Guo, Zhen Wang, Hong Lu, Di Wu, Weineng Feng, Wen Li, Jianan Huang, Yan Wang, Xia Song, Jiewen Peng, Laiyu Liu, Yubiao Guo, Wenting Li, Dongmei Lu, Mingxiu Hu, Zhongmin Maxwell Wang, Baiyong Li, Michelle Xia, Li Zhang
IMPORTANCE: For patients with non-small cell lung cancer whose disease progressed while receiving EGFR tyrosine kinase inhibitor (EGFR-TKI) therapy, particularly third-generation TKIs, optimal treatment options remain limited. OBJECTIVE: To compare the efficacy of ivonescimab plus chemotherapy with chemotherapy alone for patients with relapsed advanced or metastatic non-small cell lung cancer with the epidermal growth factor receptor (EGFR) variant. DESIGN, SETTING, AND PARTICIPANTS: Double-blind, placebo-controlled, randomized, phase 3 trial at 55 sites in China enrolled participants from January 2022 to November 2022; a total of 322 eligible patients were enrolled...
May 31, 2024: JAMA
#2
JOURNAL ARTICLE
Aniela M Silva-Nolasco, Miguel A de la Cruz-Morcillo, M Mercedes García-Martínez, Amaya Zalacain, Beatriz G Gálvez, Manuel Carmona
Argentatins are secondary metabolites synthesized by guayule (Parthenium argentatum A. Gray) with numerous potential medical applications. In addition to inhibiting insect growth, they are endowed with several pharmacological properties including antimicrobial and antitumorigenic activity. However, their potential as immunomodulators remains unexplored. The aim of the present study was to investigate whether argentatins can modulate the function of the immune system. Human mesenchymal stem cells were treated with argentatins and the production of several anti- and proinflammatory cytokines was evaluated...
2024: PloS One
#3
JOURNAL ARTICLE
Chrysovalantis Voutouri, C Corey Hardin, Vivek Naranbhai, Mohammad R Nikmaneshi, Melin J Khandekar, Justin F Gainor, Lance L Munn, Rakesh K Jain, Triantafyllos Stylianopoulos
Critical illness, such as severe COVID-19, is heterogenous in presentation and treatment response. However, it remains possible that clinical course may be influenced by dynamic and/or random events such that similar patients subject to similar injuries may yet follow different trajectories. We deployed a mechanistic mathematical model of COVID-19 to determine the range of possible clinical courses after SARS-CoV-2 infection, which may follow from specific changes in viral properties, immune properties, treatment modality and random external factors such as initial viral load...
2024: PloS One
#4
JOURNAL ARTICLE
Heledd H Jarosz-Griffiths, Lindsey Gillgrass, Laura R Caley, Giulia Spoletini, Ian J Clifton, Christine Etherington, Sinisa Savic, Michael F McDermott, Daniel Peckham
Inflammation is a key driver in the pathogenesis of cystic fibrosis (CF). We assessed the effectiveness of elexacaftor/tezacaftor/ivacaftor (ETI) therapy on downregulating systemic and immune cell-derived inflammatory cytokines. We also monitored the impact of ETI therapy on clinical outcome. Adults with CF, heterozygous for F508del (n = 19), were assessed at baseline, one month and three months following ETI therapy, and clinical outcomes were measured, including sweat chloride, lung function, weight, neutrophil count and C-reactive protein (CRP)...
2024: PloS One
#5
JOURNAL ARTICLE
Xingguang Li, Meng-Lu Gao, Shan-Shan Wang, Yu-Long Li, Tong-Ning Liu, Huijing Xiang, Pei-Nian Liu
Photothermal immunotherapy has shown great promise in the treatment of tumor metastasis. However, the thermal resistance of tumor cells substantially compromises the treatment effect of photothermal immunotherapy. Herein, a high-performance organic pyroelectric nanoplatform, t Bu-TPAD-BF2 nanoparticles (NPs), was rationally engineered for the effective pyroelectroimmunotherapy of tumor metastasis. Biocompatible t Bu-TPAD-BF2 NPs with excellent pyroelectric and photothermal conversion properties were constructed by assembling organic, low-bandgap pyroelectric molecules with amphiphilic polymers...
May 31, 2024: Advanced Materials
#6
JOURNAL ARTICLE
Raymond Joseph Kostlan, John T Phoenix, Audris Budreika, Marina G Ferrari, Neetika Khurana, Jae Eun Choi, Kristin Juckette, Somnath Mahapatra, Brooke L McCollum, Russell Moskal, Rahul Mannan, Yuanyuan Qiao, Donald J Vander Griend, Arul M Chinnaiyan, Steven Kregel
There is tremendous need for improved prostate cancer (PCa) models. The mouse prostate is anatomically and developmentally different from the human prostate and does not spontaneously form tumors. Genetically engineered mouse models lack the heterogeneity of human cancer and rarely establish metastatic growth. Human xenografts are an alternative but must rely on an immunocompromised host. Therefore, we generated PCa murine xenograft models with an intact human immune system (huNOG and huNOG-EXL mice) to test whether humanizing tumor-immune interactions would improve modeling of metastatic PCa and the impact of androgen receptor-targeted and immunotherapies...
May 31, 2024: Molecular Cancer Research: MCR
#7
JOURNAL ARTICLE
Yongfei Guo, Mao Yang, Tongguo Si
BACKGROUND: The most effective clinical treatment for hepatocellular carcinoma (HCC) is surgery, but most patients are diagnosed when the disease has progressed. OBJECTIVE: To examine the long-term prognosis and clinical effectiveness of PD-L1 inhibitor-targeted therapy for patients suffering from HCC. METHODS: Ninety-six patients with advanced HCC who were admitted to our hospital between December 2019 and April 2022 were split into two groups based on the treatment plan after a retrospective analysis: 43 patients in the control group underwent sorafenib-based targeted therapy, while dulvalizumab was used to treat 53 patients in the observation group...
May 16, 2024: Technology and Health Care: Official Journal of the European Society for Engineering and Medicine
#8
REVIEW
Desirèe Speranza, Mariacarmela Santarpia, Francesco Luppino, Fausto Omero, Enrica Maiorana, Mariacarmela Cavaleri, Elena Sapuppo, Vincenzo Cianci, Alessia Pugliese, Vito Racanelli, Giulia Maria Camerino, Carmelo Rodolico, Nicola Silvestris
INTRODUCTION: Despite immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, the consequential over activation of the immune system is often complicated by adverse events that can affect several organs and systems including the nervous system. The precise pathophysiology underlying neurological irAEs (n-irAEs) is not completely known. Around 3.8% of patients receiving anti-CTLA-4 agents, 6.1% of patients receiving anti-PD-1/PD-L1, and 12% of patients receiving combination therapies have n-irAEs...
May 31, 2024: Expert Opinion on Drug Safety
#9
JOURNAL ARTICLE
Michelle Zhang, Guorui Dai, Dana L Smith, Emanuela Zacco, Michiko Shimoda, Nitasha Kumar, Valerie Girling, Kendall Gardner, Peter W Hunt, Laurence Huang, Jue Lin
People living with HIV (PLWH) are at greater risk of developing lung diseases even when they are antiretroviral therapy (ART)-adherent and virally suppressed. The most common pulmonary function abnormality in PLWH is that of impaired diffusing capacity of the lungs for carbon monoxide (DLCO), which is an independent risk factor for increased mortality in PLWH. Earlier work has identified several plasma biomarkers of inflammation and immune activation to be associated with decreased DLCO. However, the underpinning molecular mechanisms of HIV-associated impaired DLCO are largely unknown...
May 31, 2024: AIDS
#10
JOURNAL ARTICLE
Maki Yoshino, Hiroki Ishihara, Yuki Nemoto, Shinsuke Mizoguchi, Takashi Ikeda, Takayuki Nakayama, Hironori Fukuda, Kazuhiko Yoshida, Junpei Iizuka, Hiroaki Shimmura, Yasunobu Hashimoto, Tsunenori Kondo, Toshio Takagi
BACKGROUND: The impact of glucocorticoid administration for adverse events (AEs), including immune-related AEs, on the effectiveness of immune checkpoint inhibitor (ICI) combination therapy for advanced renal cell carcinoma (RCC) remains unknown. OBJECTIVES: To clarify the prognostic impact of glucocorticoid use for AEs during first-line ICI combination therapy for advanced RCC. PATIENTS AND METHODS: We retrospectively evaluated data from 194 patients who received dual ICI combination therapy [i...
May 31, 2024: Targeted Oncology
#11
JOURNAL ARTICLE
Joash D Joy, Beatrice Malacrida, Florian Laforets, Panoraia Kotantaki, Eleni Maniati, Ranjit Manchanda, Alessandro Annibaldi, Sarah Hopkins, Ianire Garrobo-Calleja, Julien Gautrot, Frances R Balkwill
In vitro preclinical testing of chimeric antigen receptor (CAR) T cells is mostly carried out in monolayer cell cultures. However, alternative strategies are needed to take into account the complexity and the effects of the tumor microenvironment (TME). Here, we describe the modulation of CAR T cell activity by malignant cells and fibroblasts in human 3D in vitro cell models of increasing complexity. In models combining mucin-1 (MUC1) and TnMUC1 CAR T cells with human high-grade serous ovarian cancer (HGSOC) cell spheroids, malignant cell-intrinsic resistance to CAR T cell killing was due to defective death receptor signaling involving TNFα...
May 31, 2024: Cancer Research
#12
JOURNAL ARTICLE
Viktor Janz, Anastasia Rakow, Leonie Schröder, André Hofer, Sergej Wiebe, Janosch Schoon, Stefan Weiss, Barbara M Bröker, Georgi I Wassilew, Dina Raafat
PURPOSE: Periprosthetic joint infections (PJIs) are a very demanding complication of arthroplasty. Diagnosis of PJI and pathogen identification pose considerable challenges in clinical practice. We hypothesized that the pathogen-specific immune response to PJI reflects the infection process, provides clinically relevant information on disease course, and has the potential to further optimize antimicrobial therapy. METHODS: We conducted a prospective matched cohort pilot study with 13 patients undergoing two-stage septic revision arthroplasty (PJI patients) between 06/2020 and 06/2021, as well as 11 control patients undergoing one-stage aseptic revision arthroplasty (Non-PJI patients)...
May 31, 2024: Infection
#13
REVIEW
Hideaki Nakajima, Hiroyoshi Kunimoto
VEXAS syndrome is a recently identified, adult-onset autoinflammatory disease caused by somatic mutations in UBA1. UBA1 is an X-linked gene encoding E1 ubiquitin activating enzyme and its mutation in hematopoietic stem and progenitor cells leads to their clonal expansion and myeloid-skewed differentiation. UBA1 mutations in VEXAS are clustered at the second methionine (p.Met41), eliminating UBA1b isoform translated from p.Met41. Loss of UBA1b impairs ubiquitination and activates innate immune pathways, leading to systemic autoinflammation manifested as recurrent fever, chondritis, pulmonary involvement, vasculitis, or neutrophilic dermatitis...
May 31, 2024: International Journal of Hematology
#14
JOURNAL ARTICLE
Yuting Wei, Zhirang Zhang, Tianyuan Xue, Zhongda Lin, Xinyu Chen, Yishi Tian, Yuan Li, Zhangyan Jing, Wenli Fang, Tianliang Fang, Baoqi Li, Qi Chen, Tianyu Lan, Fanqiang Meng, Xudong Zhang, Xin Liang
Immune-checkpoint blockade (ICB) reinvigorates T cells from exhaustion and potentiates T-cell responses to tumors. However, most patients do not respond to ICB therapy, and only a limited response can be achieved in a "cold" tumor with few infiltrated lymphocytes. Synthetic biology can be used to engineer bacteria as controllable bioreactors to synthesize biotherapeutics in situ . We engineered attenuated Salmonella VNP20009 with synthetic gene circuits to produce PD-1 and Tim-3 scFv to block immunosuppressive receptors on exhausted T cells to reinvigorate their antitumor response...
May 31, 2024: ACS Synthetic Biology
#15
JOURNAL ARTICLE
Kun Ma, He Diao, Xiangyi Xu, Yu Jin, Mingling Qiu, Zicheng Liu, Chenbo Yang, Jiacheng Zhao, Senchao Chai, Qingxian Fang, Zhaoming Guo, Changhao Cui, Jianqiang Xu, Liangwei Yin, Hai-Ying Ma
Triple-negative breast cancer (TNBC) is known for its strong invasiveness, high recurrence rates, and poor prognosis. Heme oxygenase-1 (HO-1) is closely related to tumor invasion, metastasis, recurrence and formation of tumor immunosuppression. The expression of HO-1 is high in TNBC and low in normal tissues. In this study, AgPPIX was synthesized as a heme oxygenase-1 (HO-1) inhibitor and a photosensitizer for TNBC therapy. PDA nanoparticles were synthesized and modified with anti-CD24 and p -toluenesulfonamide (PTSC) on their both sides to obtain PTSC@AgPPIX/PDA@anti-CD24 Janus nanoparticles (PAPC) for AgPPIX-targeted delivery...
May 31, 2024: Nanoscale
#16
JOURNAL ARTICLE
Anne Miller, Rachel Daum, Tao Wang, Mengfen Wu, Candise Tat, Thomas Pfeiffer, Shoba Navai, Andras Heczey, Meenakshi Hegde, Nabil Ahmed, Sarah B Whittle, LaQuisa Hill, Caridad Martinez, Robert Krance, Carlos A Ramos, Rayne H Rouce, Premal Lulla, Helen E Heslop, Bilal Omer, Meghan Shekar
BACKGROUND AIMS: The success of chimeric antigen receptor (CAR) T-cell therapy in treating B-cell malignancies has led to the evaluation of CAR T-cells targeting a variety of other malignancies. Although the efficacy of CAR T-cells is enhanced when administered post-lymphodepleting chemotherapy, this can trigger bone marrow suppression and sustained cytopenia after CD19.CAR T-cell therapy. Additionally, systemic inflammation associated with CAR T-cell activity may contribute to myelosuppression...
May 8, 2024: Cytotherapy
#17
REVIEW
Lucille Lew-Derivry, Lamia Lamrani, Marion Alcantara, Cécile Alanio
The immune system plays a critical role in the control and eradication of tumors. A better understanding of the anti-tumor immune mechanisms over the last decade has led to the development of immunotherapies, including cellular therapies such as those using CAR-T cells. These therapies have been remarkably effective in hematological malignancies. However, their application to solid tumors requires some optimization. Many efforts are being made in this regard, both to increase the efficacy of CAR-T cells, and to make them more secure...
May 2024: Médecine Sciences: M/S
#18
REVIEW
Mathieu Vetter, Philippe Saas
The resolution of inflammation is an active process leading to the restoration of tissue homeostasis. A critical step in the initiation of this process is the elimination of apoptotic immune cells by macrophages. This well-organized process, called efferocytosis, involves four different steps, namely the attraction of macrophages to the site where the cells die, the recognition of apoptotic cells, their internalization and their digestion leading to the activation of different metabolic pathways. All these steps are responsible for the reprogramming of macrophages towards a pro-resolving profile...
May 2024: Médecine Sciences: M/S
#19
JOURNAL ARTICLE
Orsolya Kiss, Rajia Bahri, Rachel E B Watson, Chidera Chike, Abigail K Langton, Victoria L Newton, Mike Bell, Christopher E M Griffiths, Silvia Bulfone-Paus, Suzanne M Pilkington
BACKGROUND: Sex hormone changes during menopausal transition contribute to declining skin health. However, how menopause and its treatment by hormone replacement therapy (HRT) impact the skin barrier and immune system is unclear. Therefore, we examined how menopause and HRT affect skin barrier and immune cell composition in post-menopausal women following irritant challenge. METHODS: Two cohorts of post-menopausal women were recruited to the study, one untreated (HRT-; n = 10; mean age 56...
May 31, 2024: British Journal of Dermatology
#20
JOURNAL ARTICLE
Manman Zhu, Yongjian Wu, Tianchuan Zhu, Jian Chen, Zhenxing Chen, Hanxi Ding, Siyi Tan, Jianzhong He, Qi Zeng, Xi Huang
The effectiveness of immune checkpoint inhibitor (ICI) therapy is hindered by the ineffective infiltration and functioning of cytotoxic T cells and the immunosuppressive tumor microenvironment (TME). Signaling lymphocytic activation molecule family member 7 (SLAMF7) is a pivotal co-stimulatory receptor thought to simultaneously trigger natural killer (NK)-cell, T-cell, and macrophage antitumor cytotoxicity. However, the potential of this collaborative immune stimulation in antitumor immunity for solid tumors is under-explored due to the exclusive expression of SLAMF7 by hematopoietic cells...
May 31, 2024: Cancer Immunology Research
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
